The aim of this study was to define factors that significantly influence the early kinetics of donor chimerism after transplantation. In a retrospective study, the percentage of donor chimerism in peripheral blood measured with sex-chromosome-specific probes and fluorescence-in situ hybridization was analyzed in 184 recipients of allogeneic hematopoietic cells between days 1 and 30. Using a generalized linear model for longitudinal observations, the dose of CD34 þ cells infused had a significant impact on the slope of donor chimerism. In multivariate analysis, cell doses of 2-8 Â 10 6 /kg (P ¼ 0.001) and o2 Â 10 6 CD34 þ cells/kg (Po0.0001) were associated with slower increase of donor chimerism compared to 48.0 Â 10 6 CD34 þ cells/kg. In addition, fludarabine-based reduced-intensity conditioning resulted in a significant delay of donor cell increase compared to standard conditioning therapy (P ¼ 0.0001). The application of chemotherapy before the start of conditioning (P ¼ 0.0003) and the use of antithymocyte globulin (P ¼ 0.003) were associated with a faster increase of donor chimerism. The factors identified in this study can be used to predict the kinetics of early donor chimerism for an individual patient.
The aim of this study was to define factors that significantly influence the early kinetics of donor chimerism after transplantation. In a retrospective study, the percentage of donor chimerism in peripheral blood measured with sex-chromosome-specific probes and fluorescence-in situ hybridization was analyzed in 184 recipients of allogeneic hematopoietic cells between days 1 and 30. Using a generalized linear model for longitudinal observations, the dose of CD34 þ cells infused had a significant impact on the slope of donor chimerism. In multivariate analysis, cell doses of 2-8 Â 10 6 /kg (P ¼ 0.001) and o2 Â 10 6 CD34 þ cells/kg (Po0.0001) were associated with slower increase of donor chimerism compared to 48.0 Â 10 6 CD34 þ cells/kg. In addition, fludarabine-based reduced-intensity conditioning resulted in a significant delay of donor cell increase compared to standard conditioning therapy (P ¼ 0.0001). The application of chemotherapy before the start of conditioning (P ¼ 0.0003) and the use of antithymocyte globulin (P ¼ 0.003) were associated with a faster increase of donor chimerism. The factors identified in this study can be used to predict the kinetics of early donor chimerism for an individual patient. Another interesting piece of information would be whether the curve of donor chimerism after transplantation correlates with certain pretransplant parameters.
In order to investigate these questions, we performed a retrospective analysis of 184 sex-mismatched transplants performed at one center. The analysis revealed that the slope of donor chimerism is significantly influenced by CD34 þ cell dose, fludarabine-based RIC regimen , the use of antithymocyte globulin (ATG) and prior chemotherapy.
Patients and methods

Patients
All patients had given informed consent to the regular analysis of chimerism for research purposes after transplantation. The transplant protocols had been approved by the local institutional review board. The characteristics of all patients and transplant procedures are summarized in Table 1 .
Conditioning therapy
Standard preparative regimens were 12 Gy fractionated total-body irradiation (TBI) or 4 mg/kg busulfan p.o. in divided doses daily for 4 days (total dose 16 mg/kg) combined with cyclophosphamide 60 mg/kg once daily i.v. on days 1 and 2 (total dose 120 mg/kg) or etoposide 30 mg/ kg. RIC as per definition contained 30 mg/m 2 fludarabine i.v. once daily on 5-6 consecutive days and 4 mg/kg busulfan p.o. in divided doses daily for 2 days (total dose 8 mg/kg) or 2-8 Gy TBI. ATG (Merieux/Sangstat, Fremont, CA, USA) was used at a total dose of 10 mg/kg for in vivo T-cell depletion in 64 patients (32%).
Hematopoietic cells and engraftment
Patients received either unmodified bone marrow or peripheral blood stem cells (PBSC). PBSC were obtained after 1-2 standard leukapheresis procedures in donors who had received 5 days of 7.5 mg/kg lenograstim. In 21 cases, PBSC were purified by CD34 þ immunomagnetic selection as part of GvHD prophylaxis. Neutrophil and platelet engraftment was defined as the first of three consecutive days with an absolute neutrophil count (ANC) of 0.5 Â 10 9 /l or more and a platelet count of 50 Â 10 9 /l or more without transfusion.
GvHD prophylaxis and treatment
All patients with standard conditioning regimens received CsA and MTX (day 1, 3, 6 and 11). CsA was dosed to achieve trough blood levels of 200-300 ng/ml. If CsA was not tolerated, patients were switched to tacrolimus. Patients with RIC therapy received alternative GvHD prophylaxis with CsA or tacrolimus combined with mycophenolate mofetil (MMF) at 2 Â 1 g per day. MMF was tapered or stopped at day 35 if no signs of GvHD occurred. If GvHD grade II or more occurred, all patients uniformly received 2 mg/kg prednisolone for 3-5 days and were tapered when they responded. If not, steroids were escalated and salvage compounds like TNF-alpha blocker, campath-1H or daclizumab were added.
FISH analysis
Chimerism was determined from 10 ml anticoagulated peripheral blood with a median of four (range, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] analyses per patient within the first 30 days. Cell preparation was carried out according to common cytogenetic preparation techniques including hypotonic stage with 0.075 KCl and methanol/glacial acetic acid-fixation steps. Finally, the cells were dropped on to clean microscope slide and allowed to dry. For samples with WBC counts below 1 Â 10 6 /ml, the sample was aliquoted into five tubes, each with 2 ml peripheral blood and 5 ml RPMI-glutamax I. The common cytogenetic preparation technique was modified by stepwise mixture of all sediments of each aliquot after the first and following fixation steps. Every attempt was made to analyze 500 cells. Interphase FISH was performed using the direct labelled double colour CEP X SO/CEP Y (sat III) SG probe set (Abbott GmbH&Co. KG, Wiesbaden, Germany). Hybridization was performed according to the manufacturer's instructions. The limit of detection provided by the manufacturer for this assay is 1%. In our own validation series in patients after autologous or after allogeneic sex-matched transplants (n ¼ 35; 16 female and 19 male subjects), we found a mean of 0.17% (o1 of 500) false positives.
A total of 837 FISH analyses were performed in all patients between days 1 and 30 with a median of 28 values measured for each day (range 7-53).
Statistical analyses
Parameters are given as median with ranges. Differences of parameters between groups were tested by a two-tailed Mann-Whitney test. The time-dependent increase of donor chimerism is statistically modelled by a multivariate probit model. The parameters of the model have been estimated by generalized estimating equations with normal distributed residuals and an autoregressive covariance structure first order for the repeated measures of one patient. 4 The optimal model results from a stepwise elimination of nonsignificant covariables. Both tests between different models and tests of significance of a single model parameter were based on likelihood ratio tests. The model fits were judged by scaled deviance. The analyses revealed a good model-fit in each case. All analyses are derived from the SAS procedure GENMOD. 5 Table 2 summarizes the optimal multivariate probit model that reproduces well the sigmoid shape of the relation 
Results
Kinetics of chimerism
/kg) and low (o2 Â 10 6 /kg) CD34 þ cell doses, respectively. Although the number of CD3 þ T cells in the graft correlated weakly with the CD34 þ cell dose, we could not detect a significant influence of the T-cell numbers infused on the kinetics of donor chimerism.
The influence of fludarabine-based conditioning therapy can be demonstrated in Figure 2a . Patients after standard conditioning therapy had a faster increase of donor chimerism than those who received RIC.
In addition, patients who had received intensive pretreatment with chemotherapy also had an earlier increase of donor chimerism than patients who had not been treated with cytoreductive chemotherapy (Figure 2b) .
Finally, the use of in vivo T-cell depletion with ATG was associated with a faster increase of donor chimerism (Figure 2c) .
The estimated times to achieve 50 and 90% donor chimerism for all combinations of covariables, which are based on the probit model, are shown in Table 3 . An increase of the cell dose level resulted in about 2 days less to achieve 50 and 90% donor chimerism for all combinations of covariables.
We found no significant difference in chimerism kinetics between patients who had acute GvHD grades 0-I vs II-IV. /kg, conditioning therapy, chemotherapy pre-treatment and use of ATG.
Table 3
Estimated time (days) to achieve 50 and 90% donor chimerism based on the probit model In addition, we found no correlation between early chimerism kinetics and probability of disease-free survival or relapse in this heterogeneous patient population.
Hematologial engraftment
The speed of neutrophil and platelet engraftment was mainly influenced by the CD34 þ cell dose infused, whereas pre-treatment and type of conditioning regimen did not significantly influence these end points. The use of ATG did not impact on neutrophil recovery, but lead to a significant delay of platelet engraftment. Table 4 summarizes the neutrophil (40.5 Â 10 9 /l) and platelet (450 Â 10 9 /l) engraftment according to the risk factors mentioned above.
Discussion
The analysis of donor chimerism is now widely accepted as an additional diagnostic tool to monitor engraftment after allogeneic hematopoietic cell transplantation. 6 In the later phase after transplantation, decreasing donor chimerism has been related to relapse of the underlying malignancy. [7] [8] [9] [10] [11] Trials have now begun to tailor therapeutic interventions according to the loss of complete or decreasing donor chimerism. 12, 13 In addition, new transplant procedures using RIC have been shown to be associated with different kinetics of chimerism and a prolonged phase of mixed chimerism. 3, 14, 15 More detailed information on the engraftment kinetics of different cell lineages can be obtained from chimerism studies of sorted cell subsets. 16, 17 These studies already showed that the increase of chimerism in the myeloid and lymphoid compartments may depend largely on the conditioning protocol, and also on the patient population under investigation. Nevertheless, these studies did not directly compare different conditioning regimens and reported only a limited number of patients.
In a large number of patients who underwent regular analysis of donor chimerism by FISH, we confirmed the role of prior chemotherapy and the intensity of the conditioning regimen for the slope of donor chimerism. 18 In contrast to another report, we found that the use of PBSC or BM does not impact on the kinetics of donor chimerism per se, but that the dose of CD34 þ cells infused regardless of the source used is ultimately important for the speed of donor engraftment. This is in line with the observation that the higher dose of CD34 þ cells contained in PBSC leads to significantly faster engraftment of neutrophils and platelets compared to BM grafts. 2 Although several authors have described a predictive role of the number of T cells infused for the rate of immune recovery, 19 we could not detect a correlation between the number of T cells contained in the graft and the kinetics of chimerism in the early phase after transplantation. Of course, this factor may have more relevance for the longterm outcome or the incidence of GvHD. These outcome parameters were not addressed specifically in our study.
There are not many studies focusing on the kinetics of donor chimerism in the early phase after allogeneic stem cell transplantation, but there is some evidence that the increase of donor chimerism precedes hematological engraftment by several days. 2, 20 According to our analyses, the achievement of 50% donor chimerism precedes hematological engraftment by approximately 1 week. If intensity of pre-treatment, conditioning therapy and the use of ATG as well as the dose of CD34 þ cells are included, our model allows an estimate of the kinetics of donor chimerism to be expected under normal circumstances. Of course the prognostic relevance of deviations from our predicted model for later clinically relevant events like relapse, GvHD or late graft failure is not clear. In a recent analysis, investigators showed that the intensity of pre-treatment and the dose of CD34 þ cells infused significantly impacts on the kinetics of myeloid and T-cell chimerism. Whereas previous chemotherapeutic treatment led to a faster increase of T-cell chimerism, both CD34 þ cell dose and pre-treatment influenced the myeloid compartment. 21, 22 Although our investigations did not discriminate different lineages, they support the notion that the myelosuppressive and immunosuppressive effects of prior chemotherapy may allow for a faster engraftment of allogeneic cells. Similarly, the infusion of ATG leads to profound immunosuppression of the host, which thereby might also lead to faster establishment of donor hemopoiesis. This theory is supported by a recent analysis of a cohort of CML patients after unrelated hematopoietic stem cell transplantation in which those who had received ATG as part of the conditioning regimen experienced faster leukocyte recovery. 23 In our analysis, ATG administration did not influence the neutrophil recovery but led to a significant delay of platelet engraftment. Thrombocytopenia is a common side effect of ATG therapy and is probably not correlated with the FISH analyses of white blood cell nuclei after transplantation. Given the long biological half-life of ATG, one can only speculate how in vivo donor T-cell depletion may have contributed to the observed differences. The effects of ATG on donor lymphopoiesis may be reflected more correctly by subset analyses of T-cell chimerism. 24 The slower increase of donor chimerism after fludarabine-based RIC can be explained by the prolonged persistence of recipient hemopoiesis and immunity, which only leads to a gradual elimination of residual host cells by donor T and NK cells. 25 The relevant finding of this study is that early chimerism is a more sensitive parameter to assess the engraftment kinetics after dose-reduced conditioning therapy and the use of ATG at a given CD34 þ cell dose infused. This may allow for early detection of patients who are at risk for graft failure as soon as 3-5 days before the blood counts are expected to increase significantly. Whether a difference of 3-5 days in the kinetics of chimerism has any clinical impact is of course debatable.
In summary, our analyses show that the early kinetics of allogeneic engraftment as measured by donor chimerism is mainly dependent on the patient's pre-treatment, type of conditioning, use of ATG and the dose of CD34 þ cells transplanted. Deviations from the estimated values at given time points after transplantation should lead to more frequent analyses of donor chimerism and may be used to plan therapeutic interventions.
